PT  - JOURNAL ARTICLE
AU  - Leung, Janice M.
AU  - Mayo, John
AU  - Tan, Wan
AU  - Tammemagi, C. Martin
AU  - Liu, Geoffrey
AU  - Peacock, Stuart
AU  - Shepherd, Frances A.
AU  - Goffin, John
AU  - Goss, Glenwood
AU  - Nicholas, Garth
AU  - Tremblay, Alain
AU  - Johnston, Michael
AU  - Martel, Simon
AU  - Laberge, Francis
AU  - Bhatia, Rick
AU  - Roberts, Heidi
AU  - Burrowes, Paul
AU  - Manos, Daria
AU  - Stewart, Lori
AU  - Seely, Jean M.
AU  - Gingras, Michel
AU  - Pasian, Sergio
AU  - Tsao, Ming-Sound
AU  - Lam, Stephen
AU  - Sin, Don D.
ED - 
TI  - Plasma pro-surfactant protein B and lung function decline in smokers
AID  - 10.1183/09031936.00184214
DP  - 2015 Apr 01
TA  - European Respiratory Journal
PG  - 1037--1045
VI  - 45
IP  - 4
4099  - https://publications.ersnet.org//content/45/4/1037.short
4100  - https://publications.ersnet.org//content/45/4/1037.full
SO  - Eur Respir J2015 Apr 01; 45
AB  - Plasma pro-surfactant protein B (pro-SFTPB) levels have recently been shown to predict the development of lung cancer in current and ex-smokers, but the ability of pro-SFTPB to predict measures of chronic obstructive pulmonary disease (COPD) severity is unknown. We evaluated the performance characteristics of pro-SFTPB as a biomarker of lung function decline in a population of current and ex-smokers.Plasma pro-SFTPB levels were measured in 2503 current and ex-smokers enrolled in the Pan-Canadian Early Detection of Lung Cancer Study. Linear regression was performed to determine the relationship of pro-SFTPB levels to changes in forced expiratory volume in 1 s (FEV1) over a 2-year period as well as to baseline FEV1 and the burden of emphysema observed in computed tomography (CT) scans.Plasma pro-SFTPB levels were inversely related to both FEV1 % predicted (p=0.024) and FEV1/forced vital capacity (FVC) (p<0.001), and were positively related to the burden of emphysema on CT scans (p<0.001). Higher plasma pro-SFTPB levels were also associated with a more rapid decline in FEV1 at 1 year (p=0.024) and over 2 years of follow-up (p=0.004).Higher plasma pro-SFTPB levels are associated with increased severity of airflow limitation and accelerated decline in lung function. Pro-SFTPB is a promising biomarker for COPD severity and progression.High plasma pro-SFTPB levels are associated with more rapid short-term declines in FEV1 in current and ex-smokers http://ow.ly/E9Gmx